Congress Enacts FDA Drug Reforms on Vouchers, Orphan Exclusivity, and Generic Transparency
Mar 14, 2026
The Consolidated Appropriations Act, 2026, enacted February 3, reauthorizes the rare pediatric disease priority review voucher program through 2029, clarifies orphan drug exclusivity scope, and mandates increased transparency in FDA's generic drug determinations.